TRIPASS XR تري باس

 [54] Souto JC, Martinez E, Roca M, Mateo J, Pujol J, Gonzalez D, Fontcuberta J.

Prothrombotic state and signs of endothelial lesion in plasma of patients with

inflammatory bowel disease. Dig Dis Sci 1995;40:1883-1889.

[55] Collins CE, Cahill MR, Newland AC, Rampton DS. Platelets circulate in an activated

state in inflammatory bowel disease. Gastroenterology 1994;106:840-845.

[56] Dhillon AP, Anthony A, Sim R, Wakefield AJ, Sankey EA, Hudson M, Allison MC,

Pounder RE. Mucosal capillary thrombi in rectal biopsies. Histopathology

1992;21:127-133.

[57] Wakefield AJ, Sawyerr AM, Dhillon AP, Pittilo RM, Rowles PM, Lewis AA, Pounder

RE. Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet

1989;2:1057-1062.

[58] Van Deventer SJ. Tumor necrosis factor and Crohn’s disease. Gut 1997;40: 443-448.

[59] Nassif A, Longo WE, Mazuski JE, Vernava AM, Kaminski DL. Role of cytokines and

platelet-activating factor in inflammatory bowel disease. Implications for therapy. Dis

Colon Rectum 1996;39:217–223.

[60] Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA Jr.

Recombinant tumor necrosis factor induces procoagulant activity in cultured human

vascular endothelium: characterization and comparison with the actions of interleukin

1. Proc Natl Acad Sci USA 1986;83:4533–4537.

[61] Nawroth PP, Stern DM. Modulation of endothelial cell hemostatic properties by tumor

necrosis factor. J Exp Med 1986;163:740–745.

[62] Dosquet C, Weill D, Wautier JL. Cytokines and thrombosis. J Cardiovasc Pharmacol

1995;25 (Suppl 2): S13-19.

[63] Aadland E, Odegaard OR, Roseth A, Try K. Free protein S deficiency in patients with

chronic inflammatory bowel disease. Scand J Gastroenterol 1992;27:957-960.

[64] Aadland E, Odegaard OR, Roseth A, Try K. Free protein S deficiency in patients with

Crohn’s disease. Scand J Gastroenterol 1994;29:333-335.

[65] Heneghan MA, Cleary B, Murray M, O’Gorman TA, McCatrhy CF. Activated protein

C resistance, thrombophilia, and inflammatory bowel disease. Dig Dis Sci

1998;43:1356-1361.

76 Petros Zezos and Georgios Kouklakis

[66] Gallagher PM, Meleady R, Shields DC, Tan KS, McMaster D, Rozen R, Evans A,

Graham IM, Whitehead AS. Homocysteine and risk of premature coronary disease:

Evidence for a common gene mutation. Circulation 1996;94:2154 -2158.

[67] Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ.

Interrelation of hyperhomocyst(e)inemia, factor V Leiden, and risk of future venous

thromboembolism. Circulation 1997;95:1777-1782.

[68] Cantu C, Alonso E, Jara A, Martinez L, Rios C, Fernandez Mde L, Garcia I,

Barinagarrementeria F. Hyperhomocysteinemia, low folate and vitamin B12

concentrations, and methylene tetrahydrofolate reductase mutation in cerebral venous

thrombosis. Stroke 2004;35:1790-1794.

[69] den Heijer M, Koster T, Blom HJ, Bos GM, Briet E, Reitsma PH, Vandenbroucke JP,

Rosendaal FR. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N

Engl J Med 1996;334:759-762.

[70] Ray JG. Meta-analysis of hyperhomocysteinemia as a risk factor for venous

thromboembolic disease. Arch Intern Med 1998;158:2101-2106.

[71] Langman LJ, Ray JG, Evrovski J, Yeo E, Cole DE. Hyperhomocyst(e)inemia and the

increased risk of venous thromboembolism: more evidence from a case-control study.

Arch Intern Med 2000;160:961-964.

[72] McCully KS. Homocysteine and vascular disease. Nat Med 1996;2:386-389.

[73] Seshadri N, Robinson K. Homocysteine, B vitamins and coronary artery disease. Med

Clin North Am 2000;84:215-237.

[74] Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med

1998;338:1042-1050.

[75] McCully KS. Homocysteine, folate, vitamin B6, and cardiovascular disease. JAMA

1998;279:392-393.

[76] Loscalzo J. The oxidant stress of hyperhomocyst(e)inemia. J Clin Invest 1996;98:5-7.

[77] Mahmud N, Molloy A, McPartlin J, Corbally R, Whitehead AS, Scott JM, Weir DG.

Increased prevalence of methylenetetrahydrofolate reductase C677T variant in patients

with inflammatory bowel disease, and its clinical implications. Gut 1999;45:389-394.

[78] Oldenburg B, Fijnheer R, van der Griend R, vanBerge-Henegouwen GP,

Koningsberger JC. Homocysteine in inflammatory bowel disease: a risk factor for

thromboembolic complications? Am J Gastroenterol 2000;95:2825-2830.

[79] Romagnuolo J, Fedorak RN, Dias VC, Bamforth F, Teltscher M.

Hyperhomocysteinemia and inflammatory bowel disease: prevalence and predictors in

a cross-sectional study. Am J Gastroenterol 2001;96:2143-2149.

[80] Papa A, De Stefano V, Danese S, Chiusolo P, Persichilli S, Casorelli I, Zappacosta B,

Giardina B, Gasbarrini A, Leone G, Gasbarrini G. Hyperhomocysteinemia and

prevalence of polymorphisms of homocysteine metabolism-related enzymes in patients

with inflammatory bowel disease. Am J Gastroenterol 2001;96:2677-2682.

[81] Drzewoski J, Gasiorowska A, Malecka-Panas E, Bald E, Czupryniak L. Plasma total

homocysteine in the active stage of ulcerative colitis. J Gastroenterol Hepatol

2006;21:739-743.

[82] Gonera RK, Timmerhuis TP, Leyten AC, van der Heul C. Two thrombotic

complications in a patient with active ulcerative colitis. Neth J Med 1997;50:88-91.

Nutritional Issues in Inflammatory Bowel Disease… 77

[83] Slot WB, van Kasteel V, Coerkamp EG, Seelen PJ, van der Werf SD. Severe

thrombotic complications in a postpartum patient with active Crohn's disease resulting

in ischemic spinal cord injury. Dig Dis Sci 1995;40:1395-1399.

[84] Elikowski W, Malek M, Lewandowska M, Kawczynski S, Dobrowolska-Zachwieja

A,Psuja P. Massive pulmonary embolism in a patient with ulcerative colitis and

hyperhomocysteinaemia -- a case report. Kardiol Pol 2006;64:405-409.

[85] Younes-Mheni S, Younes-Mhenni S, Derex L, Berruyer M, Nighoghossian N,

Philippeau F, Salzmann M, Trouillas P. Large-artery stroke in a young patient with

Crohn's disease. Role of vitamin B6 deficiency-induced hyperhomocysteinemia. J

Neurol Sci 2004;221:113-115.

[86] Kao A, Dlugos D, Hunter JV, Mamula P, Thorarensen O. Anticoagulation therapy in

cerebral sinovenous thrombosis and ulcerative colitis in children. J Child Neurol

2002;17:479-482.

[87] Papa A, Santoliquido A, Danese S, Covino M, Di Campli C, Urgesi R, Grillo A,

Guglielmo S, Tondi P, Guidi L, De Vitis I, Fedeli G, Gasbarrini G, Gasbarrini A.

Increased carotid intima-media thickness in patients with inflammatory bowel disease.

Aliment Pharmacol Ther 2005;22:839-846.

[88] Morgenstern I, Raijmakers MT, Peters WH, Hoensch H, Kirch W. Homocysteine,

cysteine, and glutathione in human colonic mucosa: elevated levels of homocysteine in

patients with inflammatory bowel disease. Dig Dis Sci 2003;48:2083-2090.

[89] Danese S, Sgambato A, Papa A, Scaldaferri F, Pola R, Sans M, Lovecchio M,

Gasbarrini G, Cittadini A, Gasbarrini A. Homocysteine triggers mucosal microvascular

activation in inflammatory bowel disease. Am J Gastroenterol 2005;100:886-895.

[90] Burrin DG, Stoll B. Emerging aspects of gut sulfur amino acid metabolism. Curr Opin

Clin Nutr Metab Care 2007;10:63-68.

[91] Choi SW, Mason JB. Folate status: effects on pathways of colorectal carcinogenesis. J

Nutr 2002;132:2413S-2418S.

[92] Kim YI. Folate and carcinogenesis: evidence, mechanisms, and implications. J Nutr

Biochem 1999;10:66-88.

[93] Bailey LB, Rampersaud GC, Kauwell GP. Folic acid supplements and fortification

affect the risk for neural tube defects, vascular disease and cancer: evolving science. J

Nutr 2003;133:1961S-1968S.

[94] Giovannucci E. Epidemiologic studies of folate and colorectal neoplasia: a review. J

Nutr 2002;132:2350S-2355S.

[95] Potter JD. Methyl supply, methyl metabolizing enzymes and colorectal neoplasia. J

Nutr 2002;132:2410S-2412S.

[96] Eaden JA, Mayberry JF. Colorectal cancer complicating ulcerative colitis: a review. Am

J Gastroenterol 2000;95:2710-2719.

[97] Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis:

a meta-analysis. Gut 200;48:526-535.

[98] Lashner BA, Silverstein MD, Hanauer SB. Hazard rates for dysplasia and cancer in

ulcerative colitis. Results from a surveillance program. Dig Dis Sci 1989;34:1536-1541.

78 Petros Zezos and Georgios Kouklakis

[99] Greenstein AJ, Sachar DB, Smith H, Pucillo A, Papatestas AE, Kreel I, Geller SA,

Janowitz HD, Aufses AH Jr. Cancer in universal and left-sided ulcerative colitis:

factors determining risk. Gastroenterology 1979;77:290-294.

[100] Eaden J. Review article: colorectal carcinoma and inflammatory bowel disease. Aliment

Pharmacol Ther 2004;20 (Suppl 4):24-30.

[101] Meyer F, White E. Alcohol and nutrients in relation to colon cancer in middle-aged

adults. Am J Epidemiol 1993;138:225–36.

[102] Benito E, Stiggelbout A, Bosch FX, Obrador A, Kaldor J, Mulet M, Munoz N.

Nutritional factors in colorectal cancer risk: a case-control study in Majorca. Int J

Cancer 1991;49:161-167.

[103] Freudenheim J, Graham S, Marshall J, Haughey B, Cholewinski S, Wilkinson G. Folate

intake and carcinogenesis of the colon and rectum. Int J Epidemiol 1991; 20: 368–74.

[104] Lashner BA, Heidenreich PA, Su GL, Kane SV, Hanauer SB. Effect of folate

supplementation on the incidence of dysplasia and cancer in chronic ulcerative colitis.

A case-control study. Gastroenterology 1989;97:255–259.

[105] Lashner BA. Red blood cell folate is associated with the development of dysplasia and

cancer in ulcerative colitis. J Cancer Res Clin Oncol 1993;119:549 –554.

[106] Lashner BA, Provencher KS, Seidner DL, Knesebeck A, Brzezinski A. The effect of

folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis.

Gastroenterology 1997;112:29 –32.

[107] Carrier J, Medline A, Sohn KJ, Choi M, Martin R, Hwang SW, Kim YI. Effects of

dietary folate on ulcerative colitis-associated colorectal carcinogenesis in the

interleukin 2- and beta(2)-microglobulin-deficient mice. Cancer Epidemiol Biomarkers

Prev 2003;12:1262-1267.

[108] Simpson SJ, Mizoguchi E, Allen D, Bhan AK, Terhorst C. Evidence that CD4+, but not

CD8+ T cells are responsible for murine interleukin-2-deficient colitis. Eur J Immunol

1995;25:2618-2625.

[109] Shah SA, Simpson SJ, Brown LF, Comiskey M, de Jong YP, Allen D, Terhorst C.

Development of colonic adenocarcinomas in a mouse model of ulcerative colitis.

Inflamm Bowel Dis 1998;4:196-202.

[110] Sohn KJ, Shah SA, Reid S, Choi M, Carrier J, Comiskey M, Terhorst C, Kim YI.

Molecular genetics of ulcerative colitis-associated colon cancer in the interleukin 2-

and beta(2)-microglobulin-deficient mouse. Cancer Res 2001;61:6912-6917.

[111] Ryan BM, Weir DG. Relevance of folate metabolism in the pathogenesis of colorectal

cancer. J Lab Clin Med 2001;138:164-76.

[112] Kim YI. Folate, colorectal carcinogenesis, and DNA methylation. Lessons from animal

studies. Environ Mol Mutagen 2004;44:10-25.

[113] Kim YI. Role of folate in colon cancer development and progression. J Nutr

2003;133:3731S-3739S..

[114] Kim YI. Nutritional epigenetics: impact of folate deficiency on DNA methylation and

colon cancer susceptibility. J Nutr 2005;135:2703–2709.

[115] Duthie SJ, Narayanan S, Sharp L, Little J, Basten G, Powers H. Folate, DNA stability

and colo-rectal neoplasia. Proc Nutr Soc 2004;63:571-578.

Nutritional Issues in Inflammatory Bowel Disease… 79

[116] McNulty H, McKinley MC, Wilson B, McPartlin J, Strain JJ, Weir DG, Scott JM.

Impaired functioning of thermolabile methylenetetrahydrofolate reductase is dependent

on riboflavin status: implications for riboflavin requirements. Am J Clin Nutr

2002;76:436-441.

[117] Hustad S, Ueland P, Vollset S, Zhang Y, Bjorke-Monsen A, Schneede J. Riboflavin as

a determinant of plasma total homocysteine: effect modification by the

methylenetetrahydrofolate reductase C677T polymorphism. Clin Chem 2000;46:1065-

1071.

[118] Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with

inflammatory bowel disease: a population-based study. Cancer 2001;91:854-862.

[119] Maykel JA, Hagerman G, Mellgren AF, Li SY, Alavi K, Baxter NN, Madoff RD.

Crohn's colitis: the incidence of dysplasia and adenocarcinoma in surgical patients. Dis

Colon Rectum 2006;49:950-957.

[120] Jess T, Gamborg M, Matzen P, Munkholm P, Sorensen TI. Increased risk of intestinal

cancer in Crohn's disease: a meta-analysis of population-based cohort studies. Am J

Gastroenterol 2005;100:2724-2729.

[121] Siegel CA, Sands BE. Risk factors for colorectal cancer in Crohn's colitis: a casecontrol study. Inflamm Bowel Dis 2006;12:491-496.

[122] Friedman S, Rubin PH, Bodian C, Goldstein E, Harpaz N, Present DH. Screening and

surveillance colonoscopy in chronic Crohn's colitis. Gastroenterology 2001;120:820-

826.

[123] Greenstein AJ. Cancer in inflammatory bowel disease. Mt Sinai J Med 2000;67:227-

240.